June 6-11, 2010
In the past 20 years, immunization has prevented nearly 20 million deaths from vaccine-preventable infections. Despite this success, poorer countries often lack access to newer and more expensive vaccines, and vaccines are not yet available for many illnesses. PATH is working to narrow the immunization gap between developed countries and developing countries by increasing the availability of existing vaccines, reducing the lag time for adoption of recently-licensed vaccines, developing technology in support of vaccines and immunization (e.g. vaccine vial monitor, Uniject, vaccine stabilization platforms) and working with partners to develop new vaccines.
Vaccine development is expensive and manufacturers often focus on products for wealthy countries. To remedy this, PATH partners with industry, researchers, and governments worldwide to develop vaccines that meet the unique needs of low-resource countries.
PATH is developing new vaccines for malaria, meningitis, and influenza, as well as common illnesses like diarrhea and pneumonia—two leading causes of death for children under five. Current disease targets for new vaccine development are: P. falciparum, N. meningitides Group A, influenza (seasonal and pandemic), rotavirus, enterotoxigenic E. coli, Shigella species, and the pneumococcus. New technologies offer new hope for safe, effective, affordable, and accessible vaccines to better fight these illnesses. From novel vaccine approaches to new delivery methods and improved additives, PATH is accelerating a wide spectrum of technological innovations to help the people who need vaccines most urgently.
John Boslego, "NEW VACCINE TECHNOLOGIES: PROMISING ADVANCES MAY SAVE MORE LIVES" in "Vaccine Technology III", John G. Auniņš,Merck, USA; Barry C. Buckland, BiologicB, USA; Kathrin U. Jansen, Pfizer, USA; Paula Marques Alves, IBET, Portugal Eds, ECI Symposium Series, (2010). http://dc.engconfintl.org/vaccine_iii/16